Bruce N Cronstein Selected Research

Adenosine (Adenocard)

1/2021	Adenosine A2A receptor null chondrocyte transcriptome resembles that of human osteoarthritic chondrocytes.
1/2021	Adenosine A2A receptor signaling promotes FoxO associated autophagy in chondrocytes.
1/2019	Adenosine-Functionalized Biodegradable PLA-b-PEG Nanoparticles Ameliorate Osteoarthritis in Rats.
11/2017	Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression.
1/2017	Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.
12/2016	Regulation of bone and cartilage by adenosine signaling.
12/2015	Promotion of Wound Healing by an Agonist of Adenosine A2A Receptor Is Dependent on Tissue Plasminogen Activator.
4/2015	Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2.
3/2015	Brief Report: Methotrexate Prevents Wear Particle-Induced Inflammatory Osteolysis in Mice Via Activation of Adenosine A2A Receptor.
12/2013	Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruce N Cronstein Research Topics

Disease

29	Inflammation (Inflammations) 11/2021 - 01/2002
17	Fibrosis (Cirrhosis) 01/2017 - 08/2006
16	Rheumatoid Arthritis 11/2021 - 06/2005
8	Wounds and Injuries (Trauma) 12/2015 - 02/2002
7	Arthritis (Polyarthritis) 01/2020 - 01/2002
6	Neoplasms (Cancer) 01/2022 - 01/2002
6	Osteolysis 01/2019 - 05/2012
5	Osteoarthritis 01/2021 - 03/2013
5	Atherosclerosis 04/2012 - 09/2004
4	Hypoxia (Hypoxemia) 12/2016 - 01/2011
4	Cardiovascular Diseases (Cardiovascular Disease) 07/2012 - 12/2007
4	Bone Resorption 05/2012 - 02/2010
3	Psoriatic Arthritis 01/2020 - 06/2015
3	Rheumatic Diseases (Rheumatism) 01/2017 - 01/2006
3	Cicatrix (Scar) 12/2013 - 01/2009
3	Gout 07/2012 - 03/2005
3	Infections 02/2012 - 08/2006
3	Ulcer 04/2009 - 02/2002
2	Obesity 01/2021 - 01/2020
2	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 08/2007
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2017 - 06/2015
2	Diabetes Mellitus 12/2015 - 04/2009
2	Pain (Aches) 03/2013 - 01/2002
2	Gouty Arthritis 01/2013 - 01/2006
2	Contact Dermatitis (Eczema, Contact) 03/2011 - 06/2009
2	Diabetic Foot 04/2009 - 01/2004
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 06/2008 - 08/2006
2	Fever (Fevers) 01/2007 - 01/2002
1	Acute Disease 01/2022
1	Insulin Resistance 12/2016
1	Hyperinsulinism (Hyperinsulinemia) 12/2016
1	Hyperglycemia 12/2016
1	Colorectal Neoplasms (Colorectal Cancer) 11/2016
1	Hyperplasia 01/2016
1	Radiation Fibrosis Syndrome (Radiation Fibrosis) 01/2016
1	Colonic Neoplasms (Colon Cancer) 01/2016

Drug/Important Bio-Agent (IBA)

39	Adenosine (Adenocard)FDA LinkGeneric 01/2021 - 01/2002
17	Methotrexate (Mexate)FDA LinkGeneric 11/2021 - 01/2002
15	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 12/2015 - 02/2002
14	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2022 - 06/2002
8	CollagenIBA 01/2016 - 12/2007
6	Biological ProductsIBA 01/2020 - 01/2006
6	CholesterolIBA 04/2012 - 09/2004
5	CytokinesIBA 01/2018 - 11/2004
4	Pharmaceutical PreparationsIBA 01/2020 - 02/2013
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 11/2004
4	Adenine NucleotidesIBA 01/2017 - 06/2008
4	ZM 241385 (ZM241385)IBA 03/2015 - 08/2006
4	EnzymesIBA 12/2013 - 11/2004
3	Purine NucleosidesIBA 12/2016 - 10/2010
3	Adenosine A2 Receptor AgonistsIBA 12/2015 - 02/2002
3	Uric Acid (Urate)IBA 01/2013 - 01/2006
3	Caffeine (No Doz)FDA LinkGeneric 01/2011 - 08/2006
3	5'-Nucleotidase (5' Nucleotidase)IBA 03/2009 - 06/2008
2	2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosineIBA 01/2018 - 05/2012
2	LipidsIBA 12/2016 - 11/2004
2	Monoclonal AntibodiesIBA 11/2016 - 01/2016
2	Netrin-1IBA 11/2016 - 01/2016
2	Antirheumatic Agents (DMARD)IBA 01/2013 - 01/2002
2	GlucocorticoidsIBA 01/2013 - 04/2009
2	Colchicine FDA LinkGeneric 01/2013 - 07/2012
2	Small Interfering RNA (siRNA)IBA 02/2012 - 04/2010
2	LigandsIBA 02/2012 - 08/2007
2	Messenger RNA (mRNA)IBA 02/2012 - 04/2010
2	Tartrate-Resistant Acid PhosphataseIBA 02/2012 - 07/2010
2	Purinergic P1 Receptor AntagonistsIBA 01/2011 - 08/2006
2	Purinergic P1 Receptor AgonistsIBA 04/2009 - 01/2004
2	Bleomycin (Blenoxane)FDA LinkGeneric 10/2008 - 06/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2008 - 06/2002
2	Folic Acid (Vitamin M)FDA LinkGeneric 01/2007 - 06/2005
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2006 - 01/2003
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2002 - 01/2002
2	ProstaglandinsIBA 01/2002 - 01/2002
1	TicagrelorIBA 11/2021
1	Glucose (Dextrose)FDA LinkGeneric 11/2021
1	Liposomes (Liposome)IBA 01/2021
1	poly(lactic acid-ethylene glycol)IBA 01/2019
1	Dipyridamole (Persantine)FDA LinkGeneric 01/2019
1	Interleukin-22 (IL-22)IBA 01/2018
1	Neuropilin-1IBA 01/2018
1	CD100 antigenIBA 01/2018
1	Semaphorin-3AIBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Adenosine Triphosphate (ATP)IBA 11/2017
1	NucleosidesIBA 01/2017
1	Insulin-Like Growth Factor I (IGF-1)IBA 12/2016
1	AntibodiesIBA 11/2016
1	Laminin (Merosin)IBA 11/2016
1	Polyethylene (Polythene)IBA 01/2016
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 12/2015
1	Tissue Plasminogen Activator (Alteplase)FDA Link 12/2015

Therapy/Procedure

18	Therapeutics 01/2021 - 01/2002
3	Ligation 01/2021 - 03/2015
2	Intra-Articular Injections 01/2020 - 01/2019
2	Aftercare (After-Treatment) 05/2012 - 07/2008
1	Sutures (Suture) 01/2019
1	Intraperitoneal Injections 11/2016
1	Radiotherapy 01/2016
1	Prostheses and Implants (Prosthesis) 01/2016
1	Prosthesis Implantation 01/2016